UroGen Pharma has completed the enrolment of subjects in its Phase III UTOPIA trial, which is evaluating UGN-103 for intravesical solution.

Jasper Therapeutics’ stock has dropped after it announced it was investigating the impact of a faulty batch of its investigational antibody therapy dosed in a Phase Ib/IIa trial.

PulseSight Therapeutics has dosed the first subject in the Phase I trial of its first-in-class non-viral vectorised therapy, PST-611.

Bio-Thera Solutions has announced the early termination of its pivotal Phase II/III clinical trial of BAT4406F for neuromyelitis optica spectrum disorder (NMOSD). The move follows a recommendation ...

A Parkinson’s disease drug has been effective in reducing the symptoms of treatment-resistant depression. Led by the UK’s University of Oxford, the trial (ISRCTN84666271) found pramipexole to be ...

This raw weight loss is relatively comparable to Eli Lilly’s oral candidate, orforglipron, which boasted weight reductions ranging between 8.6% to 12.6% compared to 2.0% for placebo at the 26-week ...

Biogen has started dosing in the Phase III PROMINENT trial, assessing the efficacy and safety of the felzartamab drug in the adult population with primary membranous nephropathy (PMN), a severe ...

The chronic kidney disease (CKD) anemia market across the seven major markets (7MM: the US, France, Germany, Italy, Spain, the UK, and Japan) is poised to grow at a compound annual growth rate (CAGR) ...

Sponsors will need to ensure they are complying and submitting full, understandable dossiers if they are hoping to benefit from the US Food and Drug Administration’s (FDA’s) new generative artificial ...

The partnership with Javara will bring experienced clinical research staff into the health system’s clinics to work with physicians and medical teams for scaling trial operations. The initiative aims ...

Nektar’s shares have surged more than twofold after a Phase IIb study of its atopic dermatitis (AD) therapy rezpegaldesleukin (rezpeg) successfully met its primary and key secondary endpoints. The ...

Eli Lilly is looking to approach regulators for approval of its once-weekly insulin for type 2 diabetes (T2D) after it proved non-inferior to daily dosing. The QWINT-1 (NCT05662332), QWINT-3 ...